Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 2009

View Archived Issues

Odanacatib increases BMD in ovariectomized monkeys and postmenopausal women

EMEA approves ALK-Abello's Grazax as disease-modifying allergy treatment

Achillion completes phase Ia of phase Ia/b clinical trial of ACH-1625 in hepatitis C

Antitumor effect of TH-302 plus gemcitabine, docetaxel or pemetrexed seen in phase Ib trial

MT-110 safe and biologically active in phase I advanced solid tumors trial

Taisho claims mgluR5 agonists for the treatment of psychiatric disorders

Glucokinase activators for the treatment of diabetes disclosed by Daiichi Sankyo

Sanofi-aventis completes enrollment in phase III angiogenesis trial of NV1-FGF

European CHMP issues positive opinion for Januvia and Janumet for type 2 diabetes

Boehringer concludes phase III clinical trials of linagliptin in type 2 diabetes

European CHMP issues positive opinion for Pandemrix, GSK's pandemic H1N1 vaccine

Addex completes enrollment in phase IIb trial in gastroesophageal reflux disease

NCI awards phase II bridge grant to Altor BioScience to develop ALT-801

Wyeth's pneumococcal vaccine Prevenar 13 receives positive opinion for E.U. approval

Novartis' QAB-149 recommended for approval in the E.U. for treatment of COPD

European CHMP issues positive opinion for sanofi-aventis' Multaq in atrial fibrillation

Momenta reports results from EMINENCE phase II trial of anticoagulant M-118

University of Texas initiates enrollment in phase II trial of Oncolytics Biotech's Reolysin

PM-181104 shows antimicrobial activity in mouse models of MRSA and VRE infections

Hib-MenCY-TT candidate vaccine is immunogenic and well tolerated as 4th dose in infants

Synthetic vaccine SFV2/NAM1 displays broadly reactive immunity against influenza

HVJ envelope to enter clinical study for melanoma

Vitae Pharmaceuticals discovers 11beta-HSD1 inhibitors for the treatment of obesity

NS5B inhibitors for the treatment of HCV infection identified by Roche

AstraZeneca granted approval for Seroquel XR and Seroquel in Europe for bipolar disorder

Sciele submits NDA to FDA for glycopyrrolate to treat drooling in pediatric patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...